Abstract
Anticoagulation is as necessary for continuous arteriovenous hemofiltration (CAVH) as for pump-driven hemofiltration, in order to prevent clotting in the filter. The difference in anticoagulation between arteriovenous hemofiltration and conventional hemodialysis and hemofiltration results from the considerably lower blood-flow rate due to the absence of pumps and due to the longer duration of continuous treatment. Also, patients treated with CAVH to date usually suffered from an acute illness, and polytraumatized and surgical patients especially could not be endangered by unnecessarily high doses of heparin.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barrowcliffe TW, Johnson EA, Eggleton CA, Kemball-Cook C, Thomas DP (1979) Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haemetol 41: 573–583
Bengtsson G, Olivesona R, Hook M, Riesenfeld J, Lindendahl U (1980) Interaction of lipoprotein lipase with native and modified heparin-like Polysaccharides. Biochem J 189: 625–633
Carter CJ, Kelton JG, Hirsh J, Santos AV, Gent M (1982) The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 59: 1239–1245
Hirsh J, O’Sullivan EF, Gallus AS (1970) The activated thromboplastin time in the control of heparin treatment. Aust Ann Med 46: 334
Holmer E (1980) Anticoagulant properties of heparin and heparin fractions. Scand J Haematol Suppl 25: 25–39
Holmer E, Mattson C, Nilsson S (1982) Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragment in rabbits. Thromb Res 25: 475–485
Köstering H (1981) Die Thromboembolien. Schattauer, Stuttgart
Kramer P (1982) Arterio-venöse Hämofiltration. Vandenhoeck and Ruprecht, Göttingen-Zürich, S 67–80
Kramer P, Schräder J, Bohnsack W, Grieben G, Grone HJ, Scheler F (1981) Continuous arteriovenous hemofiltration (CAVH): a new kidney replacement therapy. Proc Eur Dial Transplant Assoc 18: 743
Schräder J, Köstering H, Kramer P, Scheler F (1982) Antithrombin III–Substitution bei dialysepflichtiger Niereninsuffizienz. Dtsch Med Wochenschr 107: 1847–1850
Schräder J, Bohnsack W, Kaiser H, Eisenhauer T, Kramer P, Köstering H (1982) Antikoagulation bei kontinuierlicher arterio-venöser Hämofiltration. In: Kramer P (Hrsg) Arterio-venöse Hämofiltration. Vandenhoeck und Ruprecht, Göttingen-Zürich, S 67–80
Schräder J, Rieger J, Müschen H, Stibbe W, Köstering H, Kramer P, Scheler F (1985) Anwendung von niedermolekularem Heparin bei Hämodialysepatienten. Klin Wochenschr 63: 49–55
Swartz RD (1981) Hemorrhage during high-risk hemodialysis. Using controlled heparinization. Nephron 28:65-6914. Teien AN (1979) Assay of heparin using factor Xa and a chromogenic substrate. In: Scully MF, Kakkar VV (eds) Chromogenic peptide substrates. Churchill Livingstone, Edinburgh, pp 196–205
Teien AN (1979) Assay of heparin using factor Xa and a chromogenic substrate. In: Scully MF, Kakkar VV (eds) Chromogenic peptide substrate. Churchill Livingstone, Edinburgh, pp 196–205
Vogel GE, Kopp KF (1978) The conflict between anticoagulation and hemostasis during hemodialysis. Int J Artif Organs 1: 181–186
Witt I (1977) New methods for the analysis of coagulation using chromogenic substrates. De Gruyter, Berlin
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schrader, J., Kaiser, H., Eisenhauer, T., Kramer, P., Köstering, H., Scheler, F. (1985). Anticoagulation in Continuous Arteriovenous Hemofiltration. In: Kramer, P. (eds) Arteriovenous Hemofiltration. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70370-6_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-70370-6_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-15317-7
Online ISBN: 978-3-642-70370-6
eBook Packages: Springer Book Archive